Peer-reviewed veterinary case report
VELCAP-C chemotherapy for lymphoma in cats and its side effects
By Hadden, A G et al.·Published in Journal of veterinary internal medicine·2008·Tufts University Cummings School of Veterinary Medicine, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy and toxicosis of VELCAP-C treatment of lymphoma in cats.
- Species:
- cat
Plain-English summary
A group of 61 cats diagnosed with lymphoma (a type of cancer) underwent a new treatment called VELCAP-C, which includes multiple chemotherapy drugs. While 43% of the cats responded well to the treatment, achieving a complete response, the overall survival time did not improve compared to older treatments with fewer drugs. Cats that lost weight or had liver enlargement at diagnosis tended to do worse, and higher levels of a certain enzyme (LDH) in the blood were linked to shorter survival times. This suggests that while VELCAP-C can help some cats, it may not be the best option for everyone.
People also search for: cat lymphoma treatment options · VELCAP-C for cats · cat cancer survival rates · high LDH levels in cats · chemotherapy side effects in cats
Abstract
BACKGROUND: Lymphoma is the most common malignancy affecting cats. A protocol employing vincristine, l-asparaginase, cyclophosphamide, doxorubicin, and prednisone (VELCAP-S) is effective and well tolerated in dogs with lymphoma. A 24-week variation of this protocol (VELCAP-C) was developed for treatment of cats. HYPOTHESIS: That VELCAP-C will result in survival times for cats with lymphoma that are similar to those obtained when cats are treated with a protocol that includes fewer chemotherapy agents. ANIMALS: Sixty-one cats with lymphoma. METHODS: Retrospective study. Outcomes evaluated were response to VELCAP-C therapy, toxicosis, and survival time. The effect of signalment, staging, CBC, and serum chemistry profile and dosage on these outcomes was examined. RESULTS: Six cats (10%) completed the protocol with a median survival of 1189 days. Forty-three percent (23 of 61) of the cats achieved complete response (CR) with a median survival time of 62 days. Cats that required a dose reduction of any drug during induction were more likely to achieve CR. Weight loss and hepatomegaly at diagnosis were negatively associated with response to treatment. Increased lactate dehydrogenase (LDH) serum activity at the time of initial treatment correlated with decreased survival times. CONCLUSIONS AND CLINICAL IMPORTANCE: This multi agent protocol did not provide improved survival over historical data using protocols with fewer agents. Serum LDH activity levels might provide useful prognostic information for cats with lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18289303/